Introduction {#s1}
============

A reservoir of long-lived latently HIV-1 infected cells is established early in the course of the infection. It persists despite suppressed viremia in patients undergoing effective antiretroviral therapy (ART) and fuels viral rebound upon treatment discontinuation ([@bib68]; [@bib28]; [@bib19]; [@bib27]; [@bib26]; [@bib1]). Not only is this reservoir present in blood, but also in tissues such as lymphoid organs, the gut and potentially the central nervous system ([@bib18]; [@bib61]; [@bib9]).

The mechanisms underlying HIV-1 persistence have not been fully elucidated. Although an initial decay of these reservoirs is observed after ART intervention, it is assumed that replenishment may occur through clonal proliferation of infected CD4 T cells during ART ([@bib17]; [@bib40]; [@bib47]; [@bib49] or through residual virus production despite suppressive ART ([@bib18]; [@bib14]; [@bib33]) possibly in sanctuary sites where ART penetration is suboptimal ([@bib70]; [@bib29]).

Low levels of viral reservoirs have been associated with an absence of viral rebound after treatment discontinuation in several case reports and the Visconti cohort, suggesting the possibility of post-treatment virological control even in the presence of viral reservoirs ([@bib55]; [@bib63]; [@bib62]**;** Kinloch-de Loes et al., personal communication). Achieving such a long-term control of HIV-1 replication in the absence of ART is widely defined as a functional cure ([@bib54]; [@bib25]). A low saturation of viral reservoirs facilitated by early treatment initiation might be a necessary condition, although not in itself sufficient for post-treatment virological control ([@bib62]; [@bib63]). Recent evidence indicates that the interplay between virological and immunological parameters is likely to be fundamental to achieve this goal ([@bib16]). A sustained remission from viremia rebound seems a more realistic prospect in terms of HIV-1 cure research in the short term ([@bib41]).

Early treatment initiation with ART will likely become the standard clinical practice in HIV care. This is supported by the recent outcome of the first large-scale international \'Strategic Timing of AntiRetroviral Treatment\' (START) study, showing a considerably lower risk of developing AIDS and other serious conditions when compared to later treatment initiation ([@bib38]). Interestingly, early treatment initiation during HIV-1 seroconversion is also the most effective intervention to limit the extent of viral reservoirs ([@bib3]; [@bib35]; [@bib34]; [@bib2]). Very low or even undetectable HIV-1 DNA has been described when treatment is initiated during the very early stages of primary HIV-1 infection (PHI) ([@bib3]; [@bib43]). In addition, a lower level of HIV-1 transcription has been described in ART-treated patients who initiated treatment during seroconvertion ([@bib56]).

Elite controllers and long-term non-progressors (LTNPs) represent an important group as a comparator. These HIV-1 infected individuals display low or undetectable blood reservoirs, and are able to control viremia over the long-term with limited CD4 T cell loss in the absence of treatment. Consequently, LTNPs have been extensively studied in an attempt to unravel the underlying mechanisms of spontaneous virological control ([@bib6]; [@bib22]). Although their viral reservoirs have been shown to be low, replication-competent viruses can still be found in these individuals ([@bib10]; [@bib13]). LTNPs display strong HIV-1-specific T cells responses with polyfunctionality, thereby suggesting a role of T cell immunity in viremia control ([@bib16]).

In the present study, we have assessed whether undetectable or low levels of reservoirs in blood and tissue could be achieved with very prolonged therapy initiated at PHI or during chronic infection using newly-developed polymerase chain reaction (PCR)-based virological assays for in-depth measurement of the size of the HIV-1 reservoir in blood (total and integrated HIV-1 DNA) and its dynamics (episomal 2-long terminal repeat (LTR) circles and cell-associated unspliced RNA \[usRNA\]) as well as total HIV-1 DNA burden in the rectal mucosa. These patients were compared to LTNPs and to untreated seroconverters.

We have analyzed whether 1) a decade of ART or an LTNP status was associated with the absence of detectable HIV-1 DNA in the blood and rectal mucosa; 2) long-term treated seroconverters could reach levels of virological reservoirs, residual replication, and transcription comparable to those of LTNPs; 3) a similar period of aviremia with ART initiation during the chronic phase of HIV-1 infection could achieve levels of reservoirs, residual replication, and transcription comparable to long-term treated seroconverters; 4) immune reconstitution, as measured by CD4/CD8 ratio, was enhanced with early treatment intervention; and 5) a correlation was present between the various virological and immunological parameters used in this study.

Results {#s2}
=======

Study participant characteristics {#s2-1}
---------------------------------

Eighty-four patients were included in this cross-sectional study from four different cohorts: patients who had undergone a decade of successful ART, initiated either during seroconversion (SRCV on ART; n = 25) or during the chronic phase of the infection (Chronic ART, n = 32), LTNPs (n = 17), and recently infected ART-naïve seroconverters (Recent SRCV; n = 10) ([Figure 1](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). The CD4 nadir was significantly different between each of the cohorts (p \< 0.001) except between SRCV on ART and Recent SRCV (p = 0.623). The patients were sampled at a single time point (blood and rectal biopsies) to perform PCR-based assays and characterize viral reservoirs and its dynamics (total and integrated HIV-1 DNA, 2-LTR circles, and HIV-1 usRNA).10.7554/eLife.09115.003Figure 1.Patient cohorts in the cross-sectional study.SRCV on antiretroviral therapy (ART): patient cohort with ART initiated at the time of HIV-1 seroconversion; LTNP: long-term non-progressors; Chronic ART: patients with ART initiated during the chronic phase of HIV-1 infection; Recent SRCV: recent ART-naïve seroconverters. In total, 84 patients were included in this study, 25 in SRCV on ART, 17 LTNPs, 32 Chronic ART patients, and 10 Recent SRCV. Blue arrows represent time of sampling. PHI: primary HIV-1 infection.**DOI:**[http://dx.doi.org/10.7554/eLife.09115.003](10.7554/eLife.09115.003)10.7554/eLife.09115.004Table 1.Clinical and laboratory characteristics of the four patient cohorts.**DOI:**[http://dx.doi.org/10.7554/eLife.09115.004](10.7554/eLife.09115.004)Value for cohort\*SRCV on ARTLTNPChronic ARTRecent SRCVn = 25n = 17n = 32n = 10**Clinical characteristics**Age (years)44 (34--53)49 (31--51)48 (31--53)39 (30--46)Number of females (%)0 (0)7 (41.2)5 (15.6)1 (10)Total ART duration (years)10.8 (4.2--11.9)09.8 (4.9--14.7)0Viremia zenith (log~10~HIV-1 c/ml)5.5 (2.4--5.9)2.5 (1.6--2.8)4.9 (1.9--5.5)6.2 (5.2--6.4)CD4 count, nadir (cells/mm^3^)390 (107--466)624 (507--693)155 (0--266)440 (284--495)CD4 count at sampling (cells/mm^3^)714 (476--977)793 (414--1010)624.5 (172--889)440 (284--604)CD4/CD8 ratio1.10 (0.52--1.35)0.91 (0.36--1.47)0.74 (0.23--0.93)0.62 (0.36--0.94)**Virological markers**Total HIV-1 DNA (c/10^6^ PBMCs)92 (9.8--127.7)48 (5.4--56.5)137 (8.6--219.2)1901.3 (602.4--4786.9)Integrated HIV-1 DNA (c/10^6^ PBMCs)211.3 (0--589.3)28.2 (0--158.4)586.7 (131.6--918.2)1802.7 (367.9--5890.6)HIV-1 usRNA (c/10^6^ PBMCs)1.6 (0--3.7)0.4 (0--3.51)6.1 (0--10.1)15.5 (0.9--100.6)2-LTR circles (c/10^6^ PBMCs)2.1 (0--4.3)0.8 (0--2.7)1.3 (0--2.2)13.3 (5.1--21.6)Total HIV-1 DNA (c/10^6^ cells) in rectal biopsies27.2 (22.2--61.7)21.3 (16.7--34.5)35.1 (16--77.5)[^2]

Total and integrated HIV-1 DNA in blood is reduced after a decade of ART with early treatment initiation, but does not reach the low levels found in LTNPs {#s2-2}
----------------------------------------------------------------------------------------------------------------------------------------------------------

Total HIV-1 DNA represents the most commonly used virological marker for the assessment of the size of the proviral HIV-1 reservoir and is predictive of viral rebound when tested at the time of treatment interruption in early-treated patients ([@bib67]). We have assessed the impact of the temporal treatment initiation (during early versus chronic infection) in the context of very prolonged ART treatment (e.g. a decade) on this marker and compared results to those of LTNPs and acute seroconverters before ART initiation to assess the size of HIV-1 DNA using digital PCR.

All patient cohorts had detectable levels of total HIV-1 DNA in peripheral blood mononuclear cells (PBMCs). Differences in the reservoir size in terms of total HIV-1 DNA were observed between patient cohorts. Median total HIV-1 DNA was: 92 (interquartile range (IQR): 9.8--127.7), 48 (IQR: 5.4--56.5), 137 (IQR: 8.6--219.2) and 1901.3 (IQR: 602.4--4786.9) copies (c)/10^6^ PBMCs in SRCV on ART, LTNPs, Chronic ART, and Recent SRCV, respectively. Lower total HIV-1 DNA was detected in the SRCV on ART compared to the Chronic ART cohort (p = 0.041; [Figure 2A](#fig2){ref-type="fig"}). The LTNP cohort showed the lowest total HIV-1 DNA levels when compared to SRCV on ART (p = 0.015) and other patient cohorts (p \< 0.001; [Figure 2A](#fig2){ref-type="fig"}). These results demonstrate that, the total HIV-1 DNA remains detectable in all patients even in the setting of effective early and prolonged ART, although at lower levels than in patients with later ART initiation, but not reaching the levels found in LTNPs.10.7554/eLife.09115.005Figure 2.Total HIV-1 DNA (**A**) and integrated HIV-1 DNA (**B**) in four patient cohorts.Data is shown as log~10~ copies/million (c/M) PBMCs and significant p-values are indicated by \*. Differences between the cohorts were determined by Wilcoxon Signed Rank test.**DOI:**[http://dx.doi.org/10.7554/eLife.09115.005](10.7554/eLife.09115.005)

In addition to total HIV-1 DNA levels, we also measured integrated HIV-1 DNA levels. This marker is not biased by the presence of variable quantities of unintegrated HIV-1 DNA produced after reverse transcription of newly infecting HIV-1 or dead-end DNA products of failed integration such as 1- and 2-LTR circles. Some authors have suggested that integrated HIV-1 DNA represents a better surrogate marker of viral burden, especially in patients off ART in whom HIV-1 replication might be ongoing ([@bib31]).

Median integrated HIV-1 DNA levels were: 211.3 (IQR: 0--589.3), 28.2 (IQR: 0--158.4), 586.7 (IQR: 131.6--918.2), and 1802.7 (IQR: 367.9--5890.6) c/10^6^ PBMCs for SRCV on ART, LTNPs, Chronic ART, and Recent SRCV, respectively. A lower level of integrated HIV-1 DNA was found in SRCV on ART compared to the Chronic ART cohort (p = 0.003) and in LTNPs compared to both the SRCV on ART (p = 0.021) and Chronic ART cohorts (p \< 0.001; [Figure 2B](#fig2){ref-type="fig"}). These results confirm the low levels of integrated DNA found in LTNPs as described previously ([@bib31]). Interestingly, levels of integrated HIV-1 DNA were not significantly different between the ART-naïve Recent SRCV and the Chronic ART cohort (p = 0.104). The Recent SRCV cohort displayed higher integrated HIV-1 DNA levels compared to SRCV on ART (p = 0.006) and LTNPs (p = 0.002; [Figure 2B](#fig2){ref-type="fig"}).

Of note, the absolute values derived from total and integrated HIV-1 DNA measurements in this study cannot be directly compared with each other. This is due to the difference in quantification methods, the absolute quantification of integrated HIV-1 DNA being corrected by using an integration standard as calibrator as previously described ([@bib44]; [@bib21]). This calibrator does not alter the relative differences of integrated HIV-1 DNA between patient samples, but may bias the absolute quantitative outcome. In contrast, total HIV-1 DNA is reported by direct absolute quantification and represents a better estimate of the amount of HIV-1 DNA c/10^6^ cells present in patients.

Due to the lower limit of detection compared to that of the total HIV-1 DNA assay, integrated HIV-1 DNA was undetectable in 12 patients; 5 were SRCV on ART, 6 LTNPs, and 1 Recent SRCV.

Levels of episomal 2-LTR circles in blood are low in ART-treated patients and LTNPs but high in recent ART-naïve seroconverters {#s2-3}
-------------------------------------------------------------------------------------------------------------------------------

Residual viral replication is one of the likely mechanisms through which the viral reservoir is replenished, even with effective ART ([@bib36]). Markers that reflect such a phenomenon provide insight into the reservoir dynamics. Episomal 2-LTR circles can be used as a marker of viral replication and have been shown to be labile end-products of failed proviral integrations ([@bib59]; [@bib58]). They are likely to be particularly elevated in acutely infected patients because of the intense level of viral replication. Median levels of 2-LTR circles in the various cohorts were: 2.1 (IQR: 0--4.3), 0.77 (IQR: 0--2.7), 1.3 (IQR: 0--2.2) and 13.3 (IQR: 5.1--21.6) c/10^6^ PBMCs in SRCV on ART, LTNPs, Chronic ART, and Recent SRCV, respectively. As expected, 2-LTR levels were significantly higher in the Recent SCRV compared to the other cohorts (p ≤ 0.002; [Figure 3A](#fig3){ref-type="fig"}), but did not differ between SRCV on ART and Chronic ART (p = 0.259) or LTNPs (p = 0.595) or between the Chronic ART and LTNP cohorts (p = 0.743;[Figure 3A](#fig3){ref-type="fig"}). Of note, 2-LTR circles were undetectable in a number of patients. They were detected in 17/25 (68%) of SRCV on ART, 13/17 (76%) of LTNPs, 25/32 (78%) of late-treated patients and in all recent ART-naïve seroconverters 10/10 (100%). The absence of detection in about one-quarter of patients on ART in contrast to the Recent SRCV cohort suggests that residual replication is substantially halted with ART.10.7554/eLife.09115.006Figure 3.2-LTR circles (**A**), cell-associated HIV-1 usRNA (**B**) and CD4/CD8 ratio (**C**) in four patient cohorts.Total HIV-1 DNA in rectal biopsies (**D**) in three patient cohorts (SRCV on ART, LTNP, and Chronic ART). Data is shown as log~10~ copies/million (c/M) PBMCs (**A,B**), ratio (**C**) or log~10~ c/M cells in rectal biopsies (**D**) and significant p-values are indicated by \*. Differences between the cohorts were determined by Wilcoxon Signed Rank test.**DOI:**[http://dx.doi.org/10.7554/eLife.09115.006](10.7554/eLife.09115.006)

Cell-associated HIV-1 usRNA levels in blood are lower in early-treated seroconverters than in late-treated patients but not different compared to LTNPs {#s2-4}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Levels of cell-associated HIV-1 usRNA are associated with recent HIV-1 transcriptional activity and indicate an active proviral reservoir ([@bib51]). Median levels were: 1.6 (IQR: 0--3.7), 0.4 (IQR: 0--3.5), 6.1 (IQR: 0--10.1) and 15.5 (IQR: 1--100.6) c/10^6^ PBMCs in SRCV on ART, LTNPs, Chronic ART, and Recent SRCV, respectively. The patients with the highest levels of HIV-1 usRNA were found in the Recent SRCV cohort, indicating that this cohort is not similar to the others, but this study was underpowered to reach statistical significance between the Recent SRCV and the other cohorts. Of note, HIV-1 usRNA was not detected in 8/84 samples (10%, two samples in each patient cohort). Three samples (one in SRCV on ART and two in Chronic ART) were excluded from the final analysis due to missing values for the reference genes. Higher levels of HIV-1 usRNA were detected in the Chronic ART cohort compared to the SRCV on ART (p = 0.007) and LTNPs (p = 0.027; [Figure 3B](#fig3){ref-type="fig"}). The SRCV on ART cohort was not significantly different from LTNPs based on HIV-1 usRNA levels (p = 0.615; [Figure 3B](#fig3){ref-type="fig"}).

A higher CD4/CD8 ratio is present in early-treated seroconverters and LTNPs compared to late-treated patients {#s2-5}
-------------------------------------------------------------------------------------------------------------

Not only have we used the CD4/CD8 ratio as a measure of immune preservation/reconstitution in terms of T cell count but also as an indirect marker of residual immune activation as shown recently ([@bib57]). The CD4/CD8 ratio was higher in SRCV on ART (median = 1.10, IQR: 0.52--1.35) compared to the cohorts of Chronic ART (median = 0.74, IQR: 0.23--0.93), (p = 0.009) and Recent SRCV (median = 0.62, IQR: 0.36--0.94), (p = 0.017), and was comparable to that of LTNPs (median = 0.91, IQR: 0.36--1.47), (p = 0.978; [Figure 3C](#fig3){ref-type="fig"}). The LTNP cohort had a higher CD4/CD8 ratio compared to late-treated patients (p = 0.036) and Recent SRCV (p = 0.048; [Figure 3C](#fig3){ref-type="fig"}). Of note, CD4 T cell counts at sampling did not differ significantly between the cohorts of SRCV on ART (median = 714 cells/mm^3^, IQR: 476--977) and Chronic ART (median = 625 cells/mm^3^, IQR: 172--889), (p = 0.066).

Total HIV-1 DNA levels in rectal biopsies are not different in early-treated seroconverters, late-treated patients, and LTNPs {#s2-6}
-----------------------------------------------------------------------------------------------------------------------------

Conflicting results have been published regarding the impact of ART on the HIV-1 DNA reservoir in the gut compartment when using rectal biopsies ([@bib70]; [@bib18]; [@bib4]). It remains unclear whether HIV-1 DNA decays more substantially after a decade of ART compared to a shorter intervention and whether some LTNPs may have undetectable levels in rectal biopsies. We have measured total HIV-1 DNA in rectal biopsies from 51 patients who had consented to sampling: 14 SRCV on ART, 8 LTNPs, and 29 Chronic ART patients. Five patients had undetectable total HIV-1 DNA; one SRCV on ART, one LTNP, and three Chronic ART patients. Median HIV-1 DNA levels were: 27.2 (IQR: 22.2--61.7), 21.3 (IQR: 16.7--34.5), and 35.1 (IQR: 16--77.5) c/10^6^ cells in SRCV on ART, LTNP, and Chronic ART, respectively. No difference was found between SRCV on ART and Chronic ART (p = 0.604) or LTNPs (p = 0.375; [Figure 3D](#fig3){ref-type="fig"}) or between the Chronic ART cohort and the LTNPs (p = 0.337; [Figure 3D](#fig3){ref-type="fig"}). The median number of cells assayed per patient was 125,390 (IQR: 101,308--168,156). Of note, we did not find any correlation in terms of total HIV-1 DNA levels between the blood (PBMCs) and the gut mucosa (rectal biopsies) compartments (R^2^ = 0, p = 0.919; [Figure 4A](#fig4){ref-type="fig"}).10.7554/eLife.09115.007Figure 4.Correlation of total HIV-1 DNA in rectal biopsies and blood (**A**).Correlation was assessed in 46 patients in whom total HIV-1 DNA was detected both in the blood and rectal biopsies, representing patients from three cohorts: SRCV on antiretroviral therapy (ART), Chronic ART, and long-term non-progressors (LTNP). Data is shown as log~10~ copies/million (c/M) cells in rectal biopsies and log~10~ c/M peripheral blood mononuclear cells (PBMCs) in blood. Correlation of blood HIV-1 usRNA and total HIV-1 DNA (**B**), HIV-1 usRNA and integrated HIV-1 DNA (**C**), integrated HIV-1 DNA and total HIV-1 DNA (**D**) and CD4/CD8 ratio and integrated HIV-1 DNA (**E**). Data is shown as log~10~ c/M PBMCs in detectable patients from three cohorts: SRCV on ART, Chronic ART, and LTNP (**B--E**). To assess correlations between the markers, a linear regression was performed.**DOI:**[http://dx.doi.org/10.7554/eLife.09115.007](10.7554/eLife.09115.007)

Correlation between viroimmunological markers {#s2-7}
---------------------------------------------

In order to assess whether we could observe correlations between the various viroimmunological markers used in this study, we have performed a linear regression analysis using combined data from the cohorts of patients on ART and LTNPs. The Recent SRCV cohort was excluded from this analysis because of its high level of active replication, which would have biased the HIV-1 usRNA, 2-LTR, and total HIV-1 DNA measurements. For this analysis, patient-derived samples with detectable markers were included. This was confirmed by Spearman's rank correlation, which includes all samples (data not shown).

We found a positive correlation between HIV-1 usRNA and both total HIV-1 DNA (R^2^ = 0.19, p \< 0.001; [Figure 4B](#fig4){ref-type="fig"}) and integrated HIV-1 DNA (R^2^ = 0.18, p \< 0.01; [Figure 4C](#fig4){ref-type="fig"}). Total HIV-1 DNA correlated with integrated HIV-1 DNA levels (R^2^ = 0.31, p \< 0.001; [Figure 4D](#fig4){ref-type="fig"}). No correlation was observed between 2-LTR circles and HIV-1 usRNA, total or integrated HIV-1 DNA (data not shown).

A negative correlation was found between the CD4/CD8 ratio and integrated HIV-1 DNA (R^2^ = 0.14, p \< 0.01; [Figure 4E](#fig4){ref-type="fig"}). No correlation was found between the CD4/CD8 ratio and the other virological markers assessed (total HIV-1 DNA, 2-LTR circles and usRNA in PBMCs and total HIV-1 DNA in rectal biopsies), (data not shown).

Discussion {#s3}
==========

In the present study, we have shown that a decade of ART, initiated during seroconversion, decreases the HIV-1 DNA reservoir size and viral transcription level in blood, and benefits immunological restoration in comparison to later treatment initiation of the same duration. These data support the notion that early treatment initiation at the time of seroconversion may favor post-treatment viral control by limiting the establishment of an extended viral reservoir. However, we have also found that seeding of the viral reservoir occurs very rapidly after acquisition of the infection and, indeed, our data show that the small total and integrated HIV-1 DNA reservoir in early treated patients is still significantly larger despite early treatment initiation when compared to LTNPs.

As the majority of viral reservoirs is located in tissues, we sampled rectal tissues to assess the reservoir size in the gut mucosa. Our results do not show a higher total HIV-1 DNA levels in this compartment in both early and late ART-treated patients than in LTNPs. We did not find a correlation between the blood and gut reservoirs. This is in accordance with one previous study ([@bib23]), but not with others ([@bib4]; [@bib7]). A less efficient clearance of total HIV-1 DNA in rectal tissues compared to PBMCs has previously been described after early therapy initiation ([@bib18]; [@bib3]). Low level cryptic HIV-1 replication may be a result of sub-optimal drug penetration in this compartment, immunological impairment, or caused by another unknown mechanism. Our results do not confirm such a hypothesis, although we have observed a non-significant trend towards a lower HIV-1 DNA level in gut in LTNPs compared to ART-treated patients. Lower levels of total HIV-1 DNA in gut were also previously detected in elite controllers compared to ART-suppressed patients ([@bib32]). It remains unclear how the HIV-1 reservoir in the gut compartment might be influenced by prolonged early therapy initiation, as we did not have longitudinal samples, and whether it may contribute to viral rebound after therapy interruption. Furthermore, sampling the gut mucosa remains an invasive procedure compared to blood sampling, it cannot be performed as frequently and standardization to the exact sampling location is difficult.

Residual viral replication is a topic of intense debate in the HIV-1 cure field. Evidence is accumulating that the reservoirs may consist of truly latent provirus maintained in long-lived quiescent CD4 memory T cells, seeded soon after acute infection or maintained through homeostatic proliferation ([@bib47]; [@bib65]; [@bib20]). Low level residual viral replication may also represent an important mechanism in sustaining a replication-competent viral reservoir ([@bib59]; [@bib58]; [@bib60]; [@bib36]). The presence of 2-LTR circles is considered indicative of viral replication and, as expected in this study, its levels were highest in recent ART-naïve seroconverters who display a high amount of ongoing replication. Yet no difference was observed between ART-treated patients and LTNPs. This suggests that ART effectively suppresses viral replication, regardless of the timing of treatment initiation. However, the value of 2-LTR circles as a marker for replication remains unclear as some reports suggest that 2-LTR circles are stable and long-lived ([@bib12]; [@bib52]). Notably, the amount of 2-LTR circles was low in a substantial number of ART-treated patients and LTNPs and undetectable in 26% of treated patients. Levels of 2-LTR circles did not correlate with total or integrated HIV-1 DNA or HIV-1 usRNA, indicating that factors other than the size of the viral reservoir may determine the presence of 2-LTR circles.

We have used cell-associated HIV-1 usRNA to reflect proviral DNA transcription. This marker may predict the replicative-competence of the viral reservoir, and previous studies have shown a correlation of usRNA levels with virological failure ([@bib51]) and markers of immune activation in elite controllers ([@bib37]). In addition, recent trials using histone deacetylase inhibitors to stimulate viral production in the reservoir have used HIV-1 usRNA as a marker to assess viral transcription ([@bib5]; [@bib24]; [@bib53]; [@bib66]). An earlier report has shown that early-treated patients have lower HIV-1 usRNA compared to late-treated patients after a short period of ART ([@bib56]). With a long-term follow-up, Buzon et al. observed a trend towards lower levels of HIV-1 usRNA in elite controllers and early-treated patients compared to late-treated patients ([@bib13]). Here, we can confirm that early-treated patients have lower HIV-1 usRNA compared to patients who started therapy with onset of chronic HIV-1 infection. This observation persists after a decade of successful ART. The levels of HIV-1 usRNA in early-treated seroconverters were not different from those of LTNPs, suggesting that early treatment initiation reduces viral transcriptional activity to levels reminiscent of LTNPs, which may facilitate further intervention to control such low level of viral replication. However, it must be noted that HIV-1 usRNA levels positively correlated with those of total and integrated HIV-1 DNA. This may indicate that lower levels of HIV-1 usRNA are a consequence of a smaller pool of HIV-1 DNA reservoir rather than a low transcriptional activity. Cell-associated HIV-1 usRNA levels were shown to be very low in LTNPs, thus supporting its use as a reference parameter in future studies aimed at an HIV-1 cure.

T cell activation often remains elevated in chronic HIV-1 infection in spite of ART and is linked to a lower rate of CD4 T cell count recovery ([@bib30]) and higher mortality rates ([@bib57]). Lower levels of T cell activation were shown recently in early-treated patients within 6 months of infection with a shorter ART duration (median: 2.8 years) compared to later ART initiation ([@bib39]). Here, we show that a higher CD4/CD8 ratio is found in long-term early-treated seroconverters with levels comparable to those observed in LTNPs, confirming observations from a previous study ([@bib16]). We were also able to show that the increased CD4/CD8 ratio was associated with a smaller integrated HIV-1 DNA reservoir, but not with total HIV-1 DNA. These two markers should therefore be further studied for their accuracy in reflecting the state of the HIV-1 reservoir in cure studies.

We have shown that the virological markers used in this study are affected by early treatment initiation. They could potentially represent predictors of a functional cure or of the time to viral rebound after ART interruption, where treatment interruption studies are necessary to validate these predictors. Although, the inter-patient variability of results may prevent the use of reservoir markers on an individual basis, a longitudinal follow-up of these markers may increase the rationale for their use in such studies. Recently, an association with time to viral rebound and HIV-1 DNA was found in early-treated patients within the SPARTAC study of seroconverters ([@bib67]), and with integrated HIV-1 DNA in a study using pegylated Interferon alfa-2a to purge the viral reservoir ([@bib8]). Hence, future studies should emphasize the longitudinal profiling of HIV-1 reservoir markers to validate their use in cure studies.

Some of the limitations of our study include the lack of pre-treatment and longitudinal follow-up in terms of viral reservoirs, which could provide information on their dynamics over the long-term and indicate whether a shorter period of treatment could achieve the same reservoir levels in both blood and tissues. The present study used PCR-based HIV-1 markers, which cannot differentiate between the presence or absence of replicative-competent reservoirs, and we did not use ex vivo assays such as the viral outgrowth assay (VOA) in blood, which can quantify replication-competent proviral HIV-1 DNA, the fraction of the reservoir that matters in terms of viral eradication. Both types of methods either overestimate or underestimate the size of the replicative-competent reservoir ([@bib11]), and VOA remains a cumbersome and expensive assay that is not widely available and will need to be replaced by easier and cheaper assays.

In conclusion, our study provides important data on the blood HIV-1 reservoir size and dynamics after a decade of successful treatment with ART together with gut mucosal HIV-1 DNA. Our results support early treatment initiation in terms of achieving lower levels of viral reservoirs, when compared to later treatment. The levels of HIV-1 DNA that are likely to be associated with a functional cure remain to be determined together with other factors such as protective immunological responses involved in virological control.

Material and methods {#s4}
====================

Patient cohorts {#s4-1}
---------------

Eighty-four HIV-1 infected patients from four pre-defined cohorts under clinical follow-up were enrolled into the study in two clinical centers (The Ian Charleson Day Centre, Royal Free Hospital, London, United Kingdom and the AIDS Reference Center, Ghent University Hospital, Ghent, Belgium): long-term-treated patients with ART initiated during seroconversion or chronic infection, LTNPs, and recent ART-naïve seroconverters. The first three cohorts were recruited using databases at the clinical centers (the Royal Free Center Research Database and Ghent University Hospital Database). The fourth cohort consisting of acute seroconverters was enrolled prospectively in both clinical centers. The study was approved by the Ethics Committee of Ghent University Hospital (Reference number: B670201317826) and the Royal Free Hospital (Reference number: 13/LO/0729).

The patient cohorts are described in [Figure 1](#fig1){ref-type="fig"}. The first cohort consisted of HIV-1 seroconverters on long-term ART initiated and uninterrupted since PHI (SRCV on ART; n = 25). These patients were selected on the basis of the following inclusion criteria: (a) ART for ≥4 years; (b) long-term aviremia (\<50 HIV-1 RNA copies (c)/ml); and (c) an absence of treatment failure defined by a viral load (VL) ≥400 HIV-1 RNA c/ml. Seroconversion to HIV-1 was defined by: (a) negative HIV-1 antibody by enzyme-linked immunosorbent assay (ELISA) and evidence of HIV-1 viremia ≥5000 HIV-1 RNA c/ml plasma and/or (b) incomplete HIV-1 Western blot with ≤3 bands and/or a detuned assay with a value of ≤0.6 for HIV-1 clade B patients.

The second cohort of LTNPs (n = 17) were therapy-naïve patients, with ≥7 years of documented HIV-1 infection, viremia ≤1000 HIV-1 c/ml and a CD4 T cell count ≥500 cells/mm^3^ during follow-up. Exception was made for temporary ART to prevent mother-to-child transmission.

The third cohort consisted of HIV-1 infected patients successfully treated by ART initiated during chronic infection (Chronic ART; n = 32) with: (a) a treatment duration of ≥4 years and (b) long-term undetectable VL (\<50 HIV-1 c/ml for ≥4 years). ART failure during follow-up was defined by a VL ≥400 HIV-1 c/ml.

The fourth cohort consisted of recent ART-naïve seroconverters (Recent SRCV; n = 10). Criteria for the diagnosis of seroconversion and enrollment into the study were the following: (a) negative or indeterminate HIV-1 antibody result by fourth generation ELISA and evidence of HIV-1 viremia ≥5000 HIV-1 c/ml plasma and/or (b) positive HIV-1 by fourth generation ELISA and two negative confirmatory tests (negative Vidas and Immunocomb) and/or (c) positive HIV-1 by fourth generation ELISA and negative InnoLIA.

Baseline characteristics, clinical and laboratory parameters including total duration of ART, VL zenith, CD4 T cell count at blood sampling and nadir, as well as CD4/CD8 ratio at blood sampling were collected and are summarized in [Table 1](#tbl1){ref-type="table"}.

Both the SRCV on ART and Chronic ART cohorts had a comparable uninterrupted ART duration with a median of 10.8 (IQR: 4.2--11.9) and 9.8 years (4.9--14.7), (p = 0.936), respectively.

Blood and rectal biopsies {#s4-2}
-------------------------

PBMCs and rectal biopsies were collected on one occasion for each patient ([Figure 1](#fig1){ref-type="fig"}). Blood was drawn in 6 EDTA 9 ml tubes and 10 rectal biopsies were sampled after obtaining written informed consent from the patients.

PBMCs were isolated within 4 hr of blood sampling by using Lymphoprep centrifugation (ELITech Group, Zottegem, Belgium). Cells were manually counted using a hemocytometer counting grid, aliquoted in 10^6^PBMCs as dry pellets or in fetal calf serum + 7.5% dimethyl sulfoxide and stored at −80°C. Flexible sigmoidoscopy was performed and 10 gut biopsies (volume around 1 mm^3^ of each biopt) were taken from the mucosa of the upper rectum (10 cm from the anal margin) using single-use biopsy forceps. Intact rectal biopsies were immediately frozen and stored at −80°C until further processing.

PBMCs were collected from all patients (n = 84) included in the study and rectal biopsies were obtained from 51 patients, 14 in SRCV on ART, 8 in LTNP, and 29 in Chronic ART cohorts.

Quantification of the HIV-1 reservoir, ongoing replication and transcription {#s4-3}
----------------------------------------------------------------------------

Methods used to quantify virological parameters relating to HIV-1 reservoirs, ongoing replication, and transcription in this study have been recently published and include total HIV-1 DNA and 2-LTR circles ([@bib46]), cell-associated HIV-1 usRNA ([@bib42]) with the use of droplet digital PCR (ddPCR) and integrated HIV-1 DNA measured by a repetitive sampling Alu-HIV PCR ([@bib44]; [@bib21]).

Total HIV-1 DNA, 2-LTR circles, and HIV-1 usRNA were measured in triplicates on ddPCR with the QX100Droplet Digital PCR platform (Bio-Rad, Hercules, CA). The ddPCR mix was made by adding 2 µl of sample (restricted genomic DNA \[gDNA\] or plasmid DNA) or 4 µl of sample (cDNA) to 10 µl 2× ddPCR™ supermix for probes (Bio-Rad), 500 nM of primers and 250 nM of probe in a final volume of 20 µl. ddPCR amplification reactions consisted of initial denaturation at 95°C for 5 min, followed by 40 cycles of 95°C for 30 s denaturation and assay-specific annealing/elongation temperature ([Supplementary file 1](#S1-data){ref-type="supplementary-material"}) for 60 s with a ramp rate of 2.5°C/s. Droplets were read by the QX100 droplet reader (Bio-Rad) and the data was analyzed with the QuantaSoft analysis software (Bio-Rad). Primers and probes used for each quantification assay are summarized in [Supplementary file 1](#S1-data){ref-type="supplementary-material"} and were purchased from IDT DNA Technologies (Integrated DNA Technologies, Leuven, Belgium).

Total and integrated HIV-1 DNA {#s4-4}
------------------------------

Total gDNA was isolated from 10^6^ PBMCs using DNeasy Blood & Tissue Kit (Qiagen, Venlo, The Netherlands) and eluted in 75 µl elution buffer, kept at 56°C for 10 min in order to maximize the DNA yield.

Three intact rectal biopsies were pooled per patient and used to isolate gDNA using DNeasy Blood & Tissue Kit (Qiagen). Total gDNA was eluted in 40 µl elution buffer to concentrate the sample and kept at 56°C for 10 min.

To measure total HIV-1 DNA, an enzyme restriction digestion with EcoRI (Promega, Leiden, The Netherlands) was performed on gDNA from both PBMCs and rectal biopsies with the use of 17.3 µl gDNA in a total volume of 20 µl of restriction mix. This step is preferred for ddPCR as the fragmented DNA will be more uniformly distributed in all droplets compared to full-length chromosomal DNA.

To quantify integrated HIV-1 DNA, gDNA isolated from PBMCs was subjected to a repetitive sampling Alu-HIV PCR, according to a recently described protocol ([@bib21]). Briefly, a method based on Poisson statistics was used to analyze the binomial data of positive and negative reactions from a 40-replicate Alu-HIV PCR ([@bib21]). First, total HIV-1 DNA was measured in gDNA samples by ddPCR and based on these measures, each sample was diluted to approximately five copies of total HIV-1 DNA per PCR replicate and distributed in replicates. Alu*-*HIV PCR has been described previously ([@bib44]; [@bib69]; [@bib21]) and was performed by using an HIV-1-specific reverse primer in *Gag* and a human *Alu*-specific forward primer ([Supplementary file 1](#S1-data){ref-type="supplementary-material"}) in 40 replicates. In parallel, 20 replicates were run for background quantification by using only the HIV-1 *Gag* primer. The PCR mix was made by adding 10 µl of diluted gDNA sample to 10 µl PCR mix consisting of 5× Go Taq G2 master mix, 0.2 µl Go Taq G2 DNA Polymerase, 4 mM of dNTP mix (Promega), 200 nM of *Alu* primer and 1200 nM of HIV-1 primer in a final volume of 20 µl. PCR amplification reactions consisted of initial denaturation at 95°C for 2 min, followed by 40 cycles of 95°C for 15 s denaturation, 50°C for 15 s annealing, and 70°C for 3.5 min elongation. 2 µl of the PCR product were processed in the nested qPCR (Light Cycler 480 System, Roche Applied Science, Penzberg, Germany), qPCR mix contained 2× LightCycler 480 Probes Master mix (Roche Applied Science, Vilvoorde, Belgium), 400 nM primers, and 200 nM probe ([Supplementary file 1](#S1-data){ref-type="supplementary-material"}), and qPCR consisted of initial denaturation at 95°C for 5 min, followed by 45 cycles of 95°C for 15 s denaturation, and 60°C for 1 min annealing/elongation.

The quantities of total and integrated HIV-1 DNA c/10^6^ PBMCs or total HIV-1 DNA c/10^6^cells in rectal biopsies were normalized to a reference gene *RPP30*measured by ddPCR. The number of cells assayed per patient was measured by *RPP30* in all PBMCs and rectal biopsies samples.

Episomal HIV-1 2-LTR circles {#s4-5}
----------------------------

Episomal HIV-1 2-LTR circles were measured in plasmid DNA isolated by QIAprep Spin Miniprep kit (Qiagen) from dry pelleted 10^6^ PBMCs. A known number of pSIF1-H1-Puro non-HIV plasmid was spiked to the samples (System Biosciences, Mountain view, CA) as an internal control for copy number normalization and plasmid DNA was eluted in 25 µl in order to increase DNA concentration, as described previously ([@bib46]). The internal reference plasmid was quantified by detection of the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) ([@bib45]). The 2-LTR assay is designed to span over the 2-LTR junction ([@bib14]; [Supplementary file 1](#S1-data){ref-type="supplementary-material"}).

Cell-associated HIV-1 usRNA {#s4-6}
---------------------------

RNA was isolated from 10^6^PBMCs by using RNeasy mini kit (Qiagen) subjected to DNase treatment by RNase-Free DNase Set (Qiagen) and eluted in 30 µl nuclease-free water. Samples were measured by NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA) and 1.5 mg of RNA was processed by the iScript cDNA Synthesis Kit (Bio-Rad) 5 min at 25°C, 30 min at 42°C, and 5 min at 85°C. The cDNA was used to measure HIV-1 usRNA on ddPCR.

Normalization of input cDNA was performed by quantifying gene expression of stably expressed internal reference genes as described earlier ([@bib15]; [@bib48]). Briefly, the three most stably expressed reference genes (from total of nine genes tested) were selected over all patient samples by geNorm analysis (Beta-2-microglobulin: B2M, TATA box binding protein: TBP, and Ubiquitin C: UBC) ([@bib64]). Normalization factors were determined per patient as the geometric mean of the three most stable reference genes. Subsequently, raw ddPCR values for HIV-1 usRNA were divided by the normalization factors to reach normalized data and reported as c/10^6^PBMCs for each patient sample. Previously described primers and probe sets for HIV-1 usRNA quantification were used ([@bib42]; [@bib50]), as summarized in [Supplementary file 1](#S1-data){ref-type="supplementary-material"}.

Statistical analysis {#s4-7}
--------------------

Total HIV-1 DNA, integrated HIV-1 DNA, 2-LTR circles and cell-associated HIV-1 usRNA levels as well as immunological data (CD4/CD8 T cell ratios and CD4 T cell counts at sampling and nadir CD4 T cell counts) were described using median values and IQR. Statistical analysis was performed using R (RStudio, Inc., Boston, MA). Standard non-parametric test (Wilcoxon Signed Rank Test) was performed to assess statistically significant differences between patient cohorts. A p-value of \<0.05 was considered significant. Linear regression was used to assess the correlations.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled \"Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and mucosal reservoir\" for peer review at *eLife*. Your submission has been favorably evaluated by Prabhat Jha (Senior Editor), a Reviewing Editor, and two peer reviewers, one of whom, Camilla Tincati, has agreed to reveal her identity.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

This paper on HIV reservoirs contributes to advancing the HIV cure agenda. Investigations of blood and rectal tissue in cART-treated subjects who started therapy either at time of HIV acquisition or during chronic infection were compared. Study patients were additionally compared to long-term non progressors and untreated seroconverters, representing, respectively a paradigm of virological control and early stage viremia. Initiation of cART early in the course of disease reduces total and integrated HIV DNA, yet not to the levels observed in LTNP. In contrast, timing of cART seems to affect the kinetics of usRNA. HIV reservoirs in the rectal mucosa in treated subjects were comparable to those observed in LTNP, regardless of the timing of treatment initiation. The data suggest that early, long-term cART has an important, but limited role in restraining HIV reservoirs. The novelty of this investigation, notwithstanding small numbers, lies in its attempt to perform a comprehensive analysis of HIV reservoirs in subjects starting cART in different stages of disease.

Essential revisions:

1\) Introduction:

1.1) The authors refer to \"functional cure\" several times. This term should be defined early in the Introduction.

1.2) When discussing functional cure, some clarifications are needed. For example, \"LNTPs represent a paradigm of functional cure\" is an overstatement. The definition of LTNPs in this study is VL \<1000 copies/ml but the working definition for functional cure is a more tightly controlled viral load (\<50 copies/ml). Even achieving elite control status does not necessarily equate to functional cure (because of persistent immune activation in EC which is not a desired goal of functional cure). The authors need to be more cautious about equating LTNPs to functional cure.

1.3) The Introduction is very lengthy and some parts overlap with the Discussion. Partially introducing the role of CD8 + T cells in functional cure is confusing and maybe misleading to the readers. This is because the example of functional cure cases -- the VISCONTI patients -- did not have a strong CD8 + T cell response. Moreover, the authors are not presenting HIV-specific CD8 responses data in this manuscript.

2\) Methods:

2.1) For the rectal biopsy, please provide more details about the tissue obtained for reservoir assessment: size of tissue pieces (or size of forcep), number of pieces, and number of cells assayed.

3\) Results:

3.1) 2LTR would be elevated if integrase inhibitors were used. Please clarify if this drug class was used in any of the treated groups.

4\) Discussion:

4.1) The Discussion section is very lengthy and should be more concise. For instance, the long discussion about the START trial could be shortened to just mentioning the significance of the results giving momentum to earlier treatment initiation.

4.2) The authors mentioned that 2LTR circles is a labile product and marker of ongoing viral replication, however, there have been data suggesting that 2LTR circles are stable and long-lived ([@bib12]; [@bib51]). This may explain the lack of differences between the treated groups.

4.3) Another limitation that should be mentioned is the sampling limitation of gut biopsy in terms of frequency of cells and sampling area.

4.4) The authors\' conclusion that the inability to reduce reservoir size in treated people to the level seen in LTNP means that additional interventions will be needed for functional cure is problematic. Although there is agreement that combination interventions will likely be needed for functional cure, the authors are attributing sole importance to the reservoir size as a marker of functional cure. We know that much of the total DNA is defective and that the VISCONTI patients actually had a readily detectable DNA (2 log) so there is much we do not know.

There remains concerns about using LTNP as a \"gold standard\" and the authors should reflect in the Discussion and conclusion based on their data 1) earlier treatment is superior to later treatment in reducing reservoir size, 2) LTNP is used as an example of the ability to moderately control viremia (not functional cure) in the absence of ART, 3) the levels of DNA that are important to achieving functional cure are unknown and many factors are involved. Evidence so far suggests that combination therapy will likely be needed to achieve functional cure.

10.7554/eLife.09115.010

Author response

Essential revisions:

1\) Introduction:

1.1) The authors refer to \"functional cure\" several times. This term should be defined early in the Introduction.

In the revised manuscript, the meaning of "functional cure" has been clarified early in the Introduction as "virological control in the absence of therapy".

1.2) When discussing functional cure, some clarifications are needed. For example, \"LNTPs represent a paradigm of functional cure\" is an overstatement. The definition of LTNPs in this study is VL \< 1000 copies/ml but the working definition for functional cure is a more tightly controlled viral load (\< 50 copies/ml). Even achieving elite control status does not necessarily equate to functional cure (because of persistent immune activation in EC which is not a desired goal of functional cure). The authors need to be more cautious about equating LTNPs to functional cure.

We agree with the reviewers' comment about the absence of similarity between the functional cure paradigm and LTNPs. In the new version of the manuscript, this statement has been removed.

1.3) The Introduction is very lengthy and some parts overlap with the Discussion. Partially introducing the role of CD8 + T cells in functional cure is confusing and maybe misleading to the readers. This is because the example of functional cure cases -- the VISCONTI patients -- did not have a strong CD8 + T cell response. Moreover, the authors are not presenting HIV-specific CD8 responses data in this manuscript.

To avoid any confusion and because indeed we do not present immunologic data in our study, the information on the role of CD8 + T cells in functional cure has been removed. We have also made the Introduction shorter and tried to avoid an overlap with the Discussion section.

2\) Methods:

2.1) For the rectal biopsy, please provide more details about the tissue obtained for reservoir assessment: size of tissue pieces (or size of forcep), number of pieces, and number of cells assayed.

Fifty-one patients had agreed to a flexible sigmoidoscopy and 10 rectal biopsies were taken from each patient with a volume of around 1 mm^3^ for each biopsy. Biopsies were taken from the mucosa of the upper rectum (10 cm from the anal margin) using single-use biopsy forceps (subsection "Blood and rectal biopsies"). The number of cells assayed per patient was added to the Results section (subsection "Total HIV-1 DNA levels in rectal biopsies are not different in early treated seroconverters, late treated patients and LTNPs").

3\) Results:

3.1) 2LTR would be elevated if integrase inhibitors were used. Please clarify if this drug class was used in any of the treated groups.

Some of the patients were receiving an integrase inhibitor (n = 9), but no difference in 2-LTR levels was observed when these were compared to the other ART-treated patients. There are several reports that have highlighted a transient rise in 2-LTR levels after a treatment switch to an integrase inhibitor. However, both Buzon et al. and Hatano et al. have noted that this rise is transient as the 2-LTR increase is most pronounced at week 2 after the switch to an integrase inhibitor, but decreases in the ensuing weeks. In our patients, we did not observe a difference in 2-LTR levels, which would support previous findings, as they had been treated over the long-term without a recent treatment switch in the weeks before sampling.

4\) Discussion:

4.1) The Discussion section is very lengthy and should be more concise. For instance, the long discussion about the START trial could be shortened to just mentioning the significance of the results giving momentum to earlier treatment initiation.

As suggested by the reviewers, the Discussion has been shortened. We hope that these changes are satisfactory.

4.2) The authors mentioned that 2LTR circles is a labile product and marker of ongoing viral replication, however, there have been data suggesting that 2LTR circles are stable and long-lived ([@bib12]; [@bib51]). This may explain the lack of differences between the treated groups.

We are aware of the current debate on 2-LTR circles as a marker of viral replication. In the revised manuscript we have highlighted the current controversy on the use of this marker (Discussion, third paragraph) and hope to have clarified the issue.

4.3) Another limitation that should be mentioned is the sampling limitation of gut biopsy in terms of frequency of cells and sampling area.

There are indeed practical and potentially ethical considerations in performing biopsies in patients such as LTNPs and in terms of a more invasive type of biopsy sampling in the sigmoid or small intestine. Our choice of the rectal area was driven by the fact that we had an excellent uptake by patients in another study and that it seems to be minimally invasive as compared to a more comprehensive biopsy protocol and could potentially be used in cure studies with minimal patient discomfort. By using 10 samples per patient we believe that we were be able to obtain a sufficient number of cells to detect and quantify HIV-1 DNA.

To highlight the practical issues, we have added a small section to the Discussion of the revised manuscript. These are indeed practical limitations that prevent the standardization of such sampling and hamper frequent monitoring. This has been added in the Discussion section. Notably, rectal sampling remains an invasive procedure as compared to blood sampling, which can be performed more frequently.

4.4) The authors\' conclusion that the inability to reduce reservoir size in treated people to the level seen in LTNP means that additional interventions will be needed for functional cure is problematic. Although there is agreement that combination interventions will likely be needed for functional cure, the authors are attributing sole importance to the reservoir size as a marker of functional cure. We know that much of the total DNA is defective and that the VISCONTI patients actually had a readily detectable DNA (2 log) so there is much we do not know.

There remains concerns about using LTNP as a \"gold standard\" and the authors should reflect in the Discussion and conclusion based on their data 1) earlier treatment is superior to later treatment in reducing reservoir size, 2) LTNP is used as an example of the ability to moderately control viremia (not functional cure) in the absence of ART, 3) the levels of DNA that are important to achieving functional cure are unknown and many factors are involved. Evidence so far suggests that combination therapy will likely be needed to achieve functional cure.

We absolutely agree with these comments and have attempted to make the necessary changes to the Discussion.

In our study, we have explicitly looked at various markers of the HIV-1 reservoir size and dynamics and compared results between our four patient populations. Our emphasis on reservoirs stems from the fact that data relating to HIV-1 DNA and viral rebound are available and suggest that the magnitude of the reservoirs is indeed important in terms of viral rebound and functional cure ([@bib64]). It is clear that a large proportion of this reservoir is not replicative competent however no absolute measurement of this reservoir component is available and we have therefore tried to improve our understanding of the reservoir by using several virological parameters.

We have not performed in-depth characterization of any immunological aspects which may be driving virological control and made comparison between our patient cohorts. However, recent evidence indicates that the functional cure state achieved by some patients is most probably a result of the interplay between immunological and virological aspects, the former remaining still poorly understood due to the low numbers of post-treatment controllers, the difference in T cell responses between elite controllers and post-treatment controllers and an absence of studies analysing innate immunity.

We agree with the reviewers that LTNPs represent an imperfect surrogate group for functional cure, however, we believe that they represent some of the presently best available examples of viremia control with limited immune suppression over the long-term and this in the absence of a better comparator group of patients.

In order to make these points clear, we have adapted the conclusion section of the Discussion and hope that these changes have clarified pending issues.
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[^2]: \*Values are reported as median (IQR); c: copies; PBMCs: peripheral blood mononuclear cells; usRNA: unspliced RNA; ART: antiretroviral therapy; SRCV on ART: early treated seroconverters; LTNP: long-term non-progressors; Chronic ART: late treated patients during chronic HIV-1 infection; Recent SRCV: acute ART-naïve seroconverters; LTR: Long terminal repeat.
